Study
| Phase 3, multinational, double-blind, randomized trial [MATTERHORN] |
| Resectable gastric or gastroesophageal junction adenocarcinoma |
| Durvalumab (n=474) vs Placebo (n=474) every 4 weeks plus FLOT for 4 cycles, followed by durvalumab/placebo every 4 weeks for 10 cycles |
Efficacy
| 2-yr EFS: 67.4% vs 58.5% (HR 0.71 [0.58-0.86]) |
| 2-yr OS: 75.7% vs 70.4% (HR 0.99 [0.70-1.39] from 0-12 mos; HR 0.67 [0.50-0.90] from 12 mos onward) |
| Pathological CR: 19.2% vs 7.2% (RR 2.69 [1.86-3.90]) |
Safety
| Grade >=3 AEs: 71.6% vs 71.2% |
| AEs leading to death: 5.1% vs 4.3% |
N Engl J Med Published online June 1, 2025
http://doi.org/10.1056/nejmoa2503701
Reviewed by Elvin Chalabiyev, MD on Sep 3, 2025
